Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 20, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Bonus Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a share price of GBP 14.52 per share associated with a specific transaction.
Material Changes
The document reports an increase in share interests for specific individuals following the re-investment of dividends paid on January 5, 2006. No material changes to the company's overall financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a share transaction under Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 20, 2006.
- Share Price: GBP 14.52 per share.
- Transaction Type: Increase in Ordinary Shares via dividend re-investment.
- Plan Involved: SmithKline Beecham Bonus Investment Plan.
- Participants: Mr. R Bondy and S M Bicknell (Company Secretary).